Quick Answer
Jazz Pharmaceuticals plc reported Diluted EPS of $5.84 per share (loss) for fiscal year 2025.
Jazz Pharmaceuticals plc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.84 | -167.5% |
| 2024 | $8.65 | +41.8% |
| 2023 | $6.10 | +270.4% |
| 2022 | -$3.58 | +35.1% |
| 2021 | -$5.52 | -230.8% |
| 2020 | $4.22 | -53.6% |
| 2019 | $9.09 | +24.5% |
| 2018 | $7.30 | -8.3% |
| 2017 | $7.96 | +24.2% |
| 2016 | $6.41 | +22.6% |
| 2015 | $5.23 | +462.4% |
| 2014 | $0.93 | -73.5% |
| 2013 | $3.51 | -26.7% |
| 2012 | $4.79 | +79.4% |
| 2011 | $2.67 | +221.7% |
| 2010 | $0.83 | +460.9% |
| 2009 | -$0.23 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.08 | +19.3% | +134.8% |
| June 30, 2025 | -$11.74 | -571.5% | -672.4% |
| March 31, 2025 | -$1.52 | -560.9% | -144.4% |
| September 30, 2024 | $3.42 | +59.8% | +37.3% |
| June 30, 2024 | $2.49 | +63.8% | +1182.6% |
| March 31, 2024 | -$0.23 | -122.1% | -110.7% |
| September 30, 2023 | $2.14 | +790.3% | +40.8% |
| June 30, 2023 | $1.52 | +176.4% | +46.2% |
- Jazz Pharmaceuticals plc showed a decrease of -167.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2009–2025 period, Jazz Pharmaceuticals plc’s diluted eps has declined by 2439.1% (from $0.23 per share (loss) to $5.84 per share (loss)).
- The most recent figure is from Jazz Pharmaceuticals plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: